P
Paul K. Stockman
Researcher at AstraZeneca
Publications - 37
Citations - 2334
Paul K. Stockman is an academic researcher from AstraZeneca. The author has contributed to research in topics: Tremelimumab & Durvalumab. The author has an hindex of 23, co-authored 37 publications receiving 1846 citations. Previous affiliations of Paul K. Stockman include University of Edinburgh.
Papers
More filters
Journal ArticleDOI
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial
Naiyer A. Rizvi,Byoung Chul Cho,Niels Reinmuth,Ki Hyeong Lee,Alexander Luft,Myung-Ju Ahn,Michel M. van den Heuvel,M. Cobo,David Vicente,Alexey Smolin,Vladimir Moiseyenko,Scott J. Antonia,Sylvestre Le Moulec,Gilles Robinet,Ronald B. Natale,Jeffrey Gary Schneider,Frances A. Shepherd,Sarayut Lucien Geater,Edward B. Garon,Edward S. Kim,Sarah B. Goldberg,Kazuhiko Nakagawa,Rajiv Raja,Brandon Higgs,Anne-Marie Boothman,Luping Zhao,U. Scheuring,Paul K. Stockman,Vikram Chand,Solange Peters,Mystic Investigators +30 more
TL;DR: Treatment with durvalumab resulted in a numerically reduced risk of death vs chemotherapy in patients with programmed cell death ligand 1 expression on at least 25% of tumor cells, highlighting the need for further investigation and prospective validation of blood tumor mutational burden as a predictive biomarker for immunotherapy.
Journal ArticleDOI
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.
Michele Maio,Arnaud Scherpereel,Luana Calabrò,Joachim G.J.V. Aerts,Susana Cedres Perez,Alessandra Bearz,Kristiaan Nackaerts,Dean A. Fennell,Dariusz M. Kowalski,Anne S. Tsao,Paul D. Taylor,Federica Grosso,Scott J. Antonia,Anna K. Nowak,Anna K. Nowak,Maria Taboada,Martina Puglisi,Paul K. Stockman,Hedy L. Kindler +18 more
TL;DR: The DETERMINE study investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previously treated advanced malignant mesothelioma and overall survival was overall survival in the intention-to-treat population.
Journal ArticleDOI
Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study
Ronald B. Natale,David Bodkin,Ramaswamy Govindan,Bethany G. Sleckman,Naiyer A. Rizvi,A. Capo,Paul Germonpré,Wilfried Eberhardt,Paul K. Stockman,Sarah J. Kennedy,Malcolm R Ranson +10 more
TL;DR: The primary efficacy objective was achieved, with vandetanib demonstrating a significant prolongation of PFS versus gefitinib, in this two-part phase II study in advanced NSCLC.
Journal ArticleDOI
A randomized, open-label study of the efficacy and safety of AZD4547 monotherapy versus paclitaxel for the treatment of advanced gastric adenocarcinoma with FGFR2 polysomy or gene amplification
E. Van Cutsem,Yung-Jue Bang,Wasat Mansoor,Russell D. Petty,Yee Chao,David Cunningham,David Ferry,Neil R. Smith,Paul Frewer,Jayantha Ratnayake,Paul K. Stockman,Elaine Kilgour,Donal Landers +12 more
TL;DR: AZD4547 did not significantly improve PFS versus paclitaxel in gastric cancer FGFR2 amplification/polysomy patients, and marked intratumor heterogeneity of FG FR2 amplification and poor concordance between amplification/ polysomy andFGFR2 mRNA expression indicates the need for alternative predictive biomarker testing.
Journal ArticleDOI
ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial
Ronald B. Natale,David Bodkin,Ramaswamy Govindan,Bethany G. Sleckman,Naiyer A. Rizvi,A. Capo,Paul Germonpré,Paul K. Stockman,Sarah J. Kennedy,Malcolm R Ranson +9 more
TL;DR: This study achieved its primary efficacy objective, with ZD 6474 demonstrating a significant prolongation of PFS versus gefitinib, and these data support further confirmatory trials of ZD6474 in patients with advanced NSCLC.